This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MEDNAX's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Stocks in this article: MD

MEDNAX (MD)

Q1 2012 Earnings Call

May 03, 2012 10:00 am ET

Executives

David Parker -

Roger J. Medel - Co-Founder, Chief Executive Officer, Director and Chairman of Executive Committee

Vivian Lopez-Blanco - Chief Financial Officer, Principal Accounting Officer and Treasurer

Karl Wagner - President of American Anesthesiology

Analysts

Brian Zimmerman - Deutsche Bank AG, Research Division

Ryan Daniels - William Blair & Company L.L.C., Research Division

Joanna Gajuk - BofA Merrill Lynch, Research Division

Matthew J. Weight - Feltl and Company, Inc., Research Division

Brooks G. O'Neil - Dougherty & Company LLC, Research Division

Kevin K. Ellich - Piper Jaffray Companies, Research Division

Nicholas Jansen - Raymond James & Associates, Inc., Research Division

Ralph Giacobbe - Crédit Suisse AG, Research Division

Presentation

Operator

Ladies and gentlemen, thank you very much for standing by, and welcome to the 2012 first quarter earnings conference call. [Operator Instructions] And also as a reminder, today's conference is being recorded. I would now like to turn the conference over to your host, Mr. David Parker. Please go ahead.

David Parker

Good morning, and welcome to MEDNAX 2012 First Quarter Earnings Call. Certain statements and information during this conference call may be deemed to be forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions and assessments made by MEDNAX's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements made during this call are made as of today, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,335.31 -343.39 -1.94%
S&P 500 2,028.55 -28.54 -1.39%
NASDAQ 4,689.1460 -82.6170 -1.73%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs